VALANX Biotech secures €3M to drive next‑gen cancer therapy
VALANX Biotech has raised €3 million in fresh financing to accelerate development of its lead antibody‑drug conjugate (ADC) programme, aiming to deliver more targeted and less toxic cancer treatments.
Advancing a precision oncology platform
The new capital will be used to move the company’s lead ADC candidate through preclinical optimisation and toward early clinical readiness. ADCs are an emerging class of targeted cancer medicines that combine a tumour‑seeking monoclonal antibody with a highly potent cytotoxic payload, linked together by specialised bioconjugation chemistry.
VALANX Biotech is developing a modular platform designed to control how many drug molecules are attached to each antibody and where they are positioned. This level of precision is intended to improve the therapeutic index of ADCs, enhancing anti‑tumour activity while reducing off‑target side effects that often limit traditional chemotherapy.
Funding focus: from lab to the clinic
The €3 million injection will support scale‑up of the company’s proprietary protein‑engineering and site‑specific conjugation technologies, expand its scientific team, and strengthen partnerships with academic and clinical collaborators. Resources are also expected to go toward advanced preclinical studies, toxicology packages, and manufacturing process development needed for future clinical trials.
Rising momentum in antibody‑drug conjugates
Global interest in ADC therapies has surged as several late‑stage products have demonstrated strong results in difficult‑to‑treat cancers. By focusing on more precise molecular design and manufacturing, VALANX Biotech aims to position itself within this rapidly growing segment of oncology and attract larger strategic partners once its lead candidate reaches key development milestones.
The latest financing underscores investor confidence in next‑generation precision medicine platforms that promise more effective and better‑tolerated options for patients with aggressive tumours.